Cargando…

1896. A Retrospective Cohort Analysis to Determine the Incidence of CMV Viremia and Progression to CMV Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation at an Academic Children’s Hospital

BACKGROUND: There are limited data on incidence of CMV reactivation and safety of anti-CMV prophylaxis in pediatric allogeneic hematopoietic cell transplant (HCT) recipients. We aimed to describe the rate of CMV viremia in patients receiving two different prophylaxis regimens based on risk assessmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayes, Molly, Newman, Alexander, Boge, Craig L K, Fisher, Brian T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254509/ http://dx.doi.org/10.1093/ofid/ofy210.1552

Ejemplares similares

1745. Retrospective Cohort Analysis to Determine the Incidence of CMV Infection and Disease in Allogeneic Hematopoietic Cell Transplant Recipients at an Academic Children’s Hospital
por: Galetaki, Despoina M, et al.
Publicado: (2019)

Levels of CMV Specific CD4 T Cells Are Dynamic and Correlate with CMV Viremia after Allogeneic Stem Cell Transplantation
por: Widmann, Thomas, et al.
Publicado: (2008)

940. The use of a commercially available CMV T Cell Immunity Panel to Assess the Risk of CMV Infections in Hematopoietic Cell Transplant Recipients with Low Level CMV Viremia
por: Khawaja, Fareed, et al.
Publicado: (2021)

CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality
por: Eberhardt, Kirsten Alexandra, et al.
Publicado: (2023)

Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
por: Dieamant, Débora C, et al.
Publicado: (2013)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

91. Differential Impact of Cytomegalovirus (CMV) Donor (D) Serostatus on Rates and Kinetics of CMV Viremia among CMV Seropositive Recipients (R+) of Ex vivo T-cell Depleted (TCD) and Unmodified (CONV) Hematopoietic Cell Transplants (HCT)
por: Stern, Anat, et al.
Publicado: (2019)

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia
por: Piñana, José Luis, et al.
Publicado: (2019)

Risk Factors for CMV Viremia and Treatment-Associated Adverse Events Among Pediatric Hematopoietic Stem Cell Transplant Recipients
por: Heston, Sarah M, et al.
Publicado: (2021)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

CMV in Hematopoietic Stem Cell Transplantation
por: de la Cámara, Rafael
Publicado: (2016)

1561. Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant
por: Artau, Annette, et al.
Publicado: (2018)

Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients
por: Seo, Euri, et al.
Publicado: (2021)

Combined Analysis of Early CD4(+) T Cell Counts and CMV Serostatus May Improve CMV Risk Assessment after Allogeneic Hematopoietic Cell Transplantation
por: Leserer, Saskia, et al.
Publicado: (2021)

Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation
por: Wang, Xiaodong, et al.
Publicado: (2021)

Correction: Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients
por: Seo, Euri, et al.
Publicado: (2023)

Clinical Usefulness of Monitoring Cytomegalovirus-Specific Immunity by Quantiferon-CMV in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients
por: Lee, Sae-Mi, et al.
Publicado: (2017)

CMV viral load in bronchoalveolar lavage for diagnosis of pneumonia in allogeneic hematopoietic stem cell transplantation
por: Iglesias, L, et al.
Publicado: (2017)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant
por: Ariza-Heredia, Ella J, et al.
Publicado: (2023)

1742. Kinetics of CMV Viremia with Letermovir Prophylaxis in the First 100 Days post Hematopoietic Cell Transplantation (HCT): A Single-center Experience
por: Zavras, Phaedon D, et al.
Publicado: (2019)

CMV-specific T-Cells for Treatment of CMV Infection after Hematopoietic Stem Cell Transplantation in a Pediatric Case: First Application in Turkey
por: Celilova, Sevil, et al.
Publicado: (2020)

Fifteen-Year Surveillance of LTR Receiving Pre-Emptive Therapy for CMV Infection: Prevention of CMV Disease and Incidence of CLAD
por: Piloni, Davide, et al.
Publicado: (2022)

CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation
por: Calderin Sollet, Zuleika, et al.
Publicado: (2023)

CMV-Responsive CD4 T Cells Have a Stable Cytotoxic Phenotype Over the First Year Post-Transplant in Patients Without Evidence of CMV Viremia
por: Higdon, Lauren E., et al.
Publicado: (2022)

1744. CMV Infection and Management Among Pediatric Solid-Organ Transplant Recipients
por: Sharova, Anna, et al.
Publicado: (2019)

Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients
por: McBride, Jacqueline M, et al.
Publicado: (2019)

CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients
por: Schulz, Uwe, et al.
Publicado: (2016)

Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation
por: Lodding, I P, et al.
Publicado: (2018)

CMV hyperimmune globulin as salvage therapy for recurrent or refractory CMV infection in children undergoing hematopoietic stem cell transplantation
por: Panesso, Melissa, et al.
Publicado: (2023)

688. Marginal Structure Models to Estimate the Effect of Cytomegalovirus Infection on Hospitalization Among Children Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Li, Yun, et al.
Publicado: (2020)

Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia
por: Huang, Zhenli, et al.
Publicado: (2022)

Predictors of CMV Infection in CMV-Seropositive Kidney Transplant Recipients: Impact of Pretransplant CMV-Specific Humoral Immunity
por: Kirisri, Similan, et al.
Publicado: (2021)

Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

P1334: THE IMPACT OF IMMUNOSUPPRESSION ON RECONSTITUTION OF CMV-SPECIFIC T CELLS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Dmitrova, A., et al.
Publicado: (2022)

Incidence and Outcomes of Cytomegalovirus (CMV) Infection among Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Furuno, Jon P, et al.
Publicado: (2017)

Outpatient Antimicrobial Stewardship Intervention Targeting Cytomegalovirus (CMV) Viremia in Solid Organ Transplant (SOT) Recipients
por: Wang, Nan, et al.
Publicado: (2017)

NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant
por: Pickering, Harry, et al.
Publicado: (2021)

Corrigendum: Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: impact of CMV infection and leukemia relapse
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

1752. Differential Degree and Duration of Cytomegalovirus (CMV) Viremia Between WHO International Standard-Calibrated Quantitative CMV Nucleic Acid Tests: Implications for Clinical Care
por: Meesing, Atibordee, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_apcplvfve2u39mfd5css9juu9i